ArticleBladder cancer (Amsterdam, Netherlands)
Impact of lymphovascular invasion and histological variants on BCG-treated high-grade NMIBC prognosis.
Article in Bladder cancer (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the impact of lymphovascular invasion (LVI) and histologic subtypes on prognosis following Bacillus Calmette-Guérin (BCG) therapy in high-grade non-muscle invasive bladder cancer (NMIBC). Methods: We retrospectively analyzed 245 patients who underwent transurethral resection of bladder tumor (TURBT) for high-grade Ta, T1, or carcinoma in situ (CIS) and received BCG therapy between January 2010 and December 2020. Effects of LVI and histologic subtypes on recurrence-free survival (RFS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. Results: At median follow-up of 48.5 months, LVI was detected in 25.7% of patients and histologic subtypes in 36.3%. During follow-up, disease recurrence occurred in 98 patients (40.0%) and progression in 45 patients (18.4%). In multivariate analysis, LVI (HR: 2.28, 95% CI: 1.68-3.10, p < 0.001) and histologic subtypes ≥1% (HR: 1.95, 95% CI: 1.45-2.62, p < 0.001) were independent risk factors for recurrence. Similarly, LVI (HR: 2.85, 95% CI: 1.98-4.11, p < 0.001) and histologic subtypes ≥1% (HR: 2.34, 95% CI: 1.67-3.28, p < 0.001) were independent risk factors for progression. Patients with concurrent LVI and histologic subtypes demonstrated highest risk of progression (HR: 4.15, 95% CI: 2.85-6.05, p < 0.001) with 5-year PFS rate of 45.2%. Conclusion: In high-grade NMIBC patients receiving BCG therapy, LVI and histologic subtypes are strong independent risk factors for disease recurrence and progression. Patients with both factors have highest risk and may require more aggressive treatment strategies including consideration of early radical cystectomy. These findings support the importance of detailed pathological assessment in treatment selection for BCG-treated NMIBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.